Bloomberg Law
Oct. 21, 2021, 9:56 PM

Bluebird Is Sued Over Patents Related to Blood-Disease Drug

Christopher Yasiejko
Christopher Yasiejko
Bloomberg Editorial

Bluebird Bio’s LentiGlobin and Zynteglo infringe two patents for recombinant vectors used in the treatment of rare blood disorders, closely held Errant Gene Therapeutics claims in a new lawsuit.

  • Recombinant vectors deliver gene fragments used in vaccines to boost the immune system
  • Bluebird in September submitted to FDA its application for beti-cel, made using BB305 lentiviral vector, and it’s marketing beti-cel as LentiGlobin for treating sickle cell disease and as Zynteglo for beta thalassemia, according to a complaint filed Thursday in federal court in Wilmington, Delaware
  • Errant is seeking at least a reasonable royalty and either court order blocking ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.